TY - JOUR
T1 - Immune-related strategies driving immunotherapy in breast cancer treatment
T2 - A real clinical opportunity
AU - Ravelli, Andrea
AU - Reuben, James M.
AU - Lanza, Francesco
AU - Anfossi, Simone
AU - Cappelletti, Maria Rosa
AU - Zanotti, Laura
AU - Gobbi, Angela
AU - Milani, Manuela
AU - Spada, Daniele
AU - Pedrazzoli, Paolo
AU - Martino, Massimo
AU - Bottini, Alberto
AU - Generali, Daniele
N1 - Publisher Copyright:
© 2014 Informa UK, Ltd.
PY - 2015/6/1
Y1 - 2015/6/1
N2 - Because its original use as a treatment for hematologic disease, more recently immunotherapy has emerged as a novel effective therapeutic strategy for solid malignancies, such as melanoma and prostate carcinoma. For breast carcinoma, an immunologic therapeutic approach has not been well evaluated, even though there is evidence to suggest it would be a successful novel strategy, especially taking into account the high mortality rate of the most aggressive variants of this heterogeneous disease. Here, we briefly describe the most recently awarded immune-based therapies with a consolidated or potential implication for the treatment of solid malignancies. We focus on immune checkpoints and on the clinical potential of their abrogation, with a further overview of novel vaccine-based approaches and the most relevant immunotherapeutic techniques. We aim to provide an exhaustive review of the most promising immune-therapeutic agents that may have implications for breast cancer treatment.
AB - Because its original use as a treatment for hematologic disease, more recently immunotherapy has emerged as a novel effective therapeutic strategy for solid malignancies, such as melanoma and prostate carcinoma. For breast carcinoma, an immunologic therapeutic approach has not been well evaluated, even though there is evidence to suggest it would be a successful novel strategy, especially taking into account the high mortality rate of the most aggressive variants of this heterogeneous disease. Here, we briefly describe the most recently awarded immune-based therapies with a consolidated or potential implication for the treatment of solid malignancies. We focus on immune checkpoints and on the clinical potential of their abrogation, with a further overview of novel vaccine-based approaches and the most relevant immunotherapeutic techniques. We aim to provide an exhaustive review of the most promising immune-therapeutic agents that may have implications for breast cancer treatment.
KW - adoptive T-cell therapy
KW - breast cancer
KW - breast cancer therapy
KW - breast cancer vaccine
KW - immune checkpoint blockade
KW - ipilimumab
KW - pidilizumab
KW - tremelimumab
KW - vaccination
UR - http://www.scopus.com/inward/record.url?scp=84930467798&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=84930467798&partnerID=8YFLogxK
U2 - 10.1586/14737140.2015.1042864
DO - 10.1586/14737140.2015.1042864
M3 - Review article
C2 - 25927868
AN - SCOPUS:84930467798
SN - 1473-7140
VL - 15
SP - 689
EP - 702
JO - Expert review of anticancer therapy
JF - Expert review of anticancer therapy
IS - 6
ER -